ME3221, a Surmountable Angiotensin AT_1-Receptor Antagonist, Prevents Hypertensive Complications in Aged Stroke-Prone Spontaneously Hypertensive Rats

Access this Article

Search this Article

Author(s)

    • NAGURA Jun
    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
    • HUI Chen
    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
    • YASUDA Sumie
    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
    • KONNO Fukio
    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.

Abstract

The protective effects of ME3221, 3-met hoxy-2, 6-dimethyl-4-[[2''-(1<I>H</I>-tetrazol-5-yl)-1, 1''-biphenyl-4-yl]methoxy] pyridine, on aged (32-week-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 months) oral administration. At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total <I>N</I>-acetyl-β-<SUB>D</SUB>-glucosaminidase activity, and cardiac hypertrophy and pleural effusion. The protective activity of ME3221, a surmountable angiotensin AT<SUB>1</SUB>-receptor antagonist, was comparable to losartan, an insurmountable AT<SUB>1</SUB>-antagonist, and also to enalapril, an angiotensin-converting enzyme inhibitor. In addition, ME3221 reduced the systolic blood pressure more effectively than the two reference drugs.

Journal

  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 71(1), 39-49, 1996-05

    The Japanese Pharmacological Society

References:  29

Codes

  • NII Article ID (NAID)
    10008188258
  • NII NACSIS-CAT ID (NCID)
    AA00691188
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    00215198
  • Data Source
    CJP  J-STAGE 
Page Top